BMO Capital Downgrades Amgen (AMGN) to Market Perform, Cuts Price Target to $58
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $419.38 --0%
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 18
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 18
Join SI Premium – FREE
BMO Capital downgraded shares of Amgen (NASDAQ: AMGN) to a Market Perform rating from its previous rating of Outperform and cut its price target from $72 to $58.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $54.97 yesterday.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $54.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Berenberg Downgrades PolyPeptide Group AG (PPGN:SW) to Hold
- Deutsche Bank Downgrades Oxford Biomedica (OXB:LN) (OXBDF) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
